China’s Clover Biopharma is getting another boost as it gears up for a global, pivotal trial of its COVID-19 vaccine. The Coalition for Epidemic Preparedness Innovations (CEPI) is adding $258.5 million to a deal the partners initially struck in April this year, which will see the candidate through a phase 2/3 study and licensure in China and other countries.